Moderna, Inc. (MRNA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.64B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $19.00M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.50B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $25.00M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.38B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $45.00M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.25B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $27.00M.
Moderna, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Retired, Cost Method, Amount USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Shares, Acquired shares | Treasury Stock Acquired, Average Cost Per Share USD/shares | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $0.00 | $1.64B | $19.00M | $5.10B | $6.76B | (m) | 3 month · $120.00M 6 month · $224.00M | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $0.00 | $1.50B | $25.00M | $5.88B | $7.41B | (m) | 3 month · $104.00M | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $0.00 | $1.38B | $45.00M | $7.22B | $8.65B | 12 month · $0.00 | 12 month · $483.00M | 12 month · 0.00 | 12 month · 0.00 | (m) |
| 2025-09-30 | $0.00 | $0.00 | $1.25B | $27.00M | $8.05B | $9.33B | (m) | 3 month · $125.00M 9 month · $370.00M | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $0.00 | $1.13B | $23.00M | $8.25B | $9.40B | (m) | 3 month · $130.00M 6 month · $245.00M | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $0.00 | $982.00M | $10.00M | $9.07B | $10.07B | (m) | 3 month · $115.00M | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $0.00 | $866.00M | $-10.00M | $10.04B | $10.90B | 12 month · $0.00 | 12 month · $429.00M | 12 month · 0.00 | 12 month · 0.00 | (m) |
| 2024-09-30 | $0.00 | $0.00 | $751.00M | $11.00M | $11.16B | $11.93B | (m) | 3 month · $112.00M 9 month · $325.00M | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $0.00 | $631.00M | $-71.00M | $11.15B | $11.71B | (m) | 3 month · $112.00M 6 month · $213.00M | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $0.00 | $487.00M | $-101.00M | $12.43B | $12.82B | (m) | 3 month · $101.00M | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $0.00 | $371.00M | $-123.00M | $13.61B | $13.85B | 12 month · $1.15B | 12 month · $305.00M | 12 month · 8.00M | 12 month · 143.26 | (m) |
| 2023-09-30 | $0.00 | $0.00 | $277.00M | $-211.00M | $13.39B | $13.46B | 9 month · $1.15B | 3 month · $77.00M 9 month · $226.00M | 9 month · 8.00M | 9 month · 143.31 | (m) |
| 2023-06-30 | $0.00 | $0.00 | $193.00M | $-263.00M | $17.02B | $16.95B | 6 month · $1.15B | 3 month · $74.00M 6 month · $149.00M | 6 month · 8.00M | 6 month · 143.39 | (m) |
| 2023-03-31 | $0.00 | $0.00 | $731.00M | $-267.00M | $18.40B | $18.86B | 3 month · $526.00M | 3 month · $75.00M | 3 month · 4.00M | 3 month · 145.31 | (m) |
| 2022-12-31 | $0.00 | $0.00 | $1.17B | $-370.00M | $18.32B | $19.12B | 12 month · $3.33B | 12 month · $226.00M | 12 month · 23.00M | 12 month · 142.83 | (m) |
| 2022-09-30 | $0.00 | $0.00 | $1.49B | $-351.00M | $16.86B | $17.99B | (m) | 3 month · $70.00M 9 month · $164.00M | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $0.00 | $2.41B | $-240.00M | $15.81B | $17.98B | (m) | 3 month · $50.00M 6 month · $94.00M | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $0.00 | $3.64B | $-184.00M | $13.62B | $17.07B | (m) | 3 month · $44.00M | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $0.00 | $4.21B | $-24.00M | $9.96B | $14.14B | 12 month · $857.00M | 12 month · $142.00M | 12 month · 3.00M | 12 month · 245.76 | (m) |
| 2021-09-30 | $0.00 | $0.00 | $5.00B | $31.00M | $5.09B | $10.12B | (m) | 3 month · $40.00M 9 month · $105.00M | (m) | (m) | (m) |
| 2021-06-30 | $0.00 | $0.00 | $4.93B | $16.00M | $1.76B | $6.70B | (m) | 3 month · $35.00M 6 month · $65.00M | (m) | (m) | (m) |
| 2021-03-31 | $0.00 | $0.00 | $4.86B | $1.00M | $-1.02B | $3.84B | (m) | 3 month · $30.00M | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $0.00 | $4.80B | $3.00M | $-2.24B | $2.56B | (m) | 12 month · $93.00M | (m) | (m) | (m) |
| 2020-09-30 | $0.00 | $40.00K | $4.73B | $4.78M | $-1.97B | $2.76B | (m) | 3 month · $22.00M 9 month · $67.00M | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | $39.00K | $4.68B | $8.26M | $-1.74B | $2.95B | (m) | 3 month · $25.00M 6 month · $45.00M | (m) | (m) | (m) |
| 2020-03-31 | $0.00 | $37.00K | $3.27B | $-6.13M | $-1.62B | $1.64B | (m) | 3 month · $20.00M | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | $34.00K | $2.67B | $1.80M | $-1.50B | $1.18B | (m) | 12 month · $81.00M | (m) | (m) | (m) |
| 2019-09-30 | $0.00 | $33.00K | $2.62B | $2.83M | $-1.37B | $1.25B | (m) | 3 month · $20.80M 9 month · $60.80M | (m) | (m) | (m) |
| 2019-06-30 | $0.00 | $33.00K | $2.58B | $2.74M | $-1.25B | $1.33B | (m) | 3 month · $21.50M 6 month · $39.99M | (m) | (m) | (m) |
| 2019-03-31 | $0.00 | $33.00K | $2.56B | $591.00K | $-1.11B | $1.44B | (m) | 3 month · $18.50M | (m) | (m) | (m) |
| 2019-01-01 | (m) | (m) | (m) | (m) | $-982.43M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | $33.00K | $2.54B | $-1.32M | $-1.01B | $1.53B | (m) | 12 month · $72.56M | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $-757.13M | (m) | 3 month · $14.72M 9 month · $40.92M | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $-688.77M | (m) | 3 month · $14.35M 6 month · $26.20M | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $-613.71M | (m) | 3 month · $11.85M | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | $6.00K | $71.68M | $-1.16M | $-621.89M | $-551.37M | (m) | 12 month · $40.05M | (m) | (m) | 12 month · $152.00K |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $-334.81M | (m) | 12 month · $40.01M | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | $-149.76M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |